Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06764017
PHASE2

CHiR Therapy for Elderly DLBCL Intolerant to Chemo

Sponsor: First Affiliated Hospital of Ningbo University

View on ClinicalTrials.gov

Summary

The objective of exploring the application of CHiR is to evaluate its therapeutic efficacy and safety in newly diagnosed elderly patients with diffuse large B-cell lymphoma (DLBCL) aged 70 and above, and to investigate the genetic subtypes that may benefit from CHiR. The primary endpoint is the complete remission rate (CRR) at the end of 8 cycles.

Official title: A Single-arm, Multicenter, Prospective Clinical Study of CHiR (chidamide, Zanubrutinib, and Lenalidomide) for Newly Diagnosed MYC- and BCL2-positive Diffuse Large B-cell Lymphoma (DLBCL) in Elderly Patients Intolerant to Chemotherapy.

Key Details

Gender

All

Age Range

70 Years - 100 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2025-02-01

Completion Date

2027-08-01

Last Updated

2025-03-19

Healthy Volunteers

No

Interventions

DRUG

CHiR-DEL

Using the combined regimen of CHiR (chidamide, zanubrutinib, and lenalidomide) to treat newly diagnosed elderly patients with MYC- and BCL2-expressing positive diffuse large B-cell lymphoma (DLBCL) who are intolerant to chemotherapy.

Locations (1)

The First Affiliated Hospital of Ningbo University

Ningbo, Zhejiang, China